A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

NCT00486018 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

397

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab injection 0.3 mg
DRUG: Ranibizumab injection 0.5 mg
DRUG: Sham injection

Sponsor

Genentech, Inc.